US Family Health Plan

Prior Authorization Request Form for

Phentermine/topiramate ER (Qsymia)

To be completed and signed by the prescriber. To be used only for prescriptions which are to be filled through the Department of Defense (DoD) US Family Health Plan Pharmacy Program. US Family Health Plan is a TRICARE contractor for DoD.

The completed form may be faxed to 855-273-5735

OR

The patient may attach the completed form to the prescription and **mail** it to:
Attn: Pharmacy, 77 Warren St, Brighton, MA 02135

QUESTIONS? **Call 1-877-880-7007**

Clinical documentation may be required. Failure to provide could result in denial.
Initial therapy approves for 12 months, and annual renewal is required. For renewal of therapy an initial prior authorization approval is required.

Step 1

Please complete patient and physician information (please print):

Patient Name: _____ Physician Name: _____

Address: _____ Address: _____

_____ _____

Sponsor ID # _____ Phone #: _____

Date of Birth: Secure Fax #:

Step 2

Please complete the clinical assessment:

1. Has the patient received this medication under the TRICARE benefit in the last 6 months? *Please choose "No" if the patient did not previously have a TRICARE approved PA for Qsymia.*	☐ Yes (subject to verification) Proceed to question **13**	☐ No Proceed to question **2**
2. How old is the patient?	☐ Less than 12 years of age - **STOP Coverage not approved** ☐ Greater than or equal to 12 years of age and less than 18 years of age - Proceed to question **3** ☐ Greater than or equal to 18 years of age - Proceed to question **6**	
3. Does the patient have a BMI GREATER THAN OR EQUAL TO the 95th percentile standardized for age and sex?	☐ Yes Proceed to question **4**	☐ No **STOP** **Coverage not approved**
4. Has the patient engaged in a trial of behavioral modification and dietary restriction for at least 6 months and has failed to achieve the desired weight loss, and will remain engaged throughout course of therapy?	☐ Yes Proceed to question **5**	☐ No **STOP** **Coverage not approved**
5. Does the provider agree to monitor the rate of weight loss in pediatric patients? Note: If weight loss exceeds 2 pounds (0.9kg)/week, consider dosage reduction.	☐ Yes Proceed to question **11**	☐ No **STOP** **Coverage not approved**

US Family Health Plan Prior Authorization Request Form for
phentermine/topiramate ER (Qsymia)

6. Does the patient have a BMI GREATER THAN or EQUAL to 30, or a BMI GREATER THAN or EQUAL to 27 in the presence of at least one weight-related comorbidity (for example, diabetes, impaired glucose tolerance, dyslipidemia, hypertension, sleep apnea, etc.)?	☐ Yes Proceed to question **7**	☐ No **STOP** **Coverage not approved**
7. Has the patient engaged in a trial of behavioral modification and dietary restriction for at least 6 months and has failed to achieve the desired weight loss, and will remain engaged throughout course of therapy?	☐ Yes Proceed to question **8**	☐ No **STOP** **Coverage not approved**
8. Has the patient tried and failed to achieve a 5 percent reduction in baseline weight after a 12 week course of phentermine, benzphetamine, diethylpropion (IR/SR) or phendimetrazine IR/SR?	☐ Yes Proceed to question **11**	☐ No Proceed to question **9**
9. Does the patient have a contraindication to generic phentermine, benzphetamine, diethylpropion (IR/SR) or phendimetrazine IR/SR (for example, arrhythmias, coronary artery disease, heart failure, stroke, uncontrolled hypertension, hyperthyroidism, etc.)?	☐ Yes Proceed to question **11**	☐ No Proceed to question **10**
10. Has the patient experienced an adverse reaction to phentermine, benzphetamine, diethylpropion (IR/SR) or phendimetrazine IR/SR that is not expected to occur with Qsymia?	☐ Yes Proceed to question **11**	☐ No **STOP** **Coverage not approved**
11. Is the patient pregnant?	☐ Yes **STOP** **Coverage not approved**	☐ No Proceed to question **12**
12. Will the prescriber abide by and has the patient been informed of the REMS and the following safety concerns associated with this medication: Use in combination with other products intended for weight loss has not been established, Use in patients with increased cardiovascular risk has not been established, Qsymia is pregnancy category X and is associated with increased risk of teratogenicity?	☐ Yes **Sign and date below**	☐ No **STOP** **Coverage not approved**
13. Is the patient currently engaged in behavioral modification and on a reduced calorie diet?	☐ Yes Proceed to question **14**	☐ No **STOP** **Coverage not approved**
14. Has the patient lost GREATER THAN or EQUAL to 5 percent of baseline body weight for adult patients or 5 percent of baseline BMI for patients greater than or equal to 12 years of age and less than 18 years of age since starting medication?	☐ Yes Proceed to question **15**	☐ No **STOP** **Coverage not approved**
15. Is the patient pregnant?	☐ Yes **STOP** **Coverage not approved**	☐ No **Sign and date below**

Step 3 **I certify the above is true to the best of my knowledge.** Please sign and date:

_____ _____
Prescriber Signature Date